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Abstract
Background: Complete tumor removal and preservation of the facial nerve are essential in parotid gland surgery. A
technical adjunct that potentially enhances the contrast between the facial nerve and the adherent tumor tissue
and allows to identify residual tumor tissue could be Fluorescein Sodium.
Methods: Retrospective chart analysis on 7 patients with benign parotid gland lesions that were operated using
Fluorescein Sodium intravenously and the application of the YELLOW 560 nm filter of the operating microscope.
Safety and feasibility were evaluated.
Results: All tumors showed fluorescence and the rating ´contrast-enhancing´ was assigned in all cases. In 2
patients, satellite nodules were identified and resected meaning that the fluorescence staining of the tumor
margins was significantly better than under white light.
Conclusion: The use of Fluorescein Sodium in parotidectomy is promising. In two cases residual tumor was
detected that would have been left behind under white light. Further research in parotid gland surgery and other
head and neck tumor procedures is warranted.
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Background
Preservation of the facial nerve (N.VII) is a key in par-
otid gland surgery. A technical adjunct that potentially
enhances the contrast between N.VII and the adherent
tumor tissue and allows to identify residual tumor tissue
could be Fluorescein Sodium (FL, 10%, ALCON,
Germany) and application of the YELLOW 560 nm filter
of the operating microscope (YE, Carl Zeiss Meditec,
Oberkochen).
Here, we present the preliminary data and first experi-
ences concerning feasibility and safety of FL/YE in pa-
tients with benign parotid gland lesions.
Methods
We performed a retrospective analysis of charts and op-
erating protocols. FL/YE was applied in 7 patients (3
male, 4 female; mean age 53.6 years, range 18 to
78 years) with parotid gland tumors (Table 1). Written
informed consent was obtained from all patients for the
off label use of the method. 5 mg/kg bodyweight of FL
was applied intravenously at induction of anesthesia. IRB
approval was achieved (14-101-0298). The surgical pro-
cedure was performed with 2.5 x loupe and operating
microscope magnification. Briefly, a standard pre-
auricular skin flap and separate SMAS flap was elevated.
The facial nerve was identified after exposure of the tra-
gal pointer and the digastric ridge. After dissection of
the main stem, the PENTERO 900 microscope (Carl
Zeiss Meditec, Oberkochen), which allows to switch be-
tween the light filters [1] was utilized. Under white light
no fluorescence was observed. We evaluated the con-
trast of N.VII with respect to surrounding tumor, gland
and vasculature. The ENT surgeon’s objection was rated
postoperatively by a questionnaire. The identification of
the N. VII main trunk, the visualization of the surgical
field, the identification of the tumor and its margins
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were classified by the surgeon as ‘helpful’ or ‘not
helpful’. The fluorescence behavior of the tumor was
rated as ‘contrast enhancing’ or ‘not contrast enhan-
cing’. After tumor removal the skin closure was per-
formed in layers with white light loupe magnification.
Histopathological reports and postoperative complica-
tions were evaluated (Table 1).
Results
In all patients, the procedure was mainly conducted
under the YE filter. All tumors showed fluorescence and
the rating ´contrast-enhancing´ was assigned in all cases.
In all cases the tissue fluorescence was visible for the en-
tire duration of the surgical procedure. The surgical time
was between 120 min and 180 min. The evaluation of
the questionnaires showed that for the identification of
the N. VII main trunk, using the YE filter was estimated
as ‘not helpful’ in 7 of 7 patients. The handling of the
microscope and the visualization of the surgical field
was rated as ‘helpful’ in 7/7 procedures. The contrast be-
tween nerve and tumor was rated as ‘helpful’ in 5 of 7
procedures. The additional information to visualize the
tumor and its margins with the YE filter was estimated
as ‘helpful’ in 2 of 7 cases by the ENT surgeon. In those
2 patients, satellite nodules were identified and resected.
The evaluation of the histology reports of those 2 pa-
tients showed one pleomorphic adenoma and one
Warthin tumor. Representative photographs document
the intraoperative view with white light (Fig. 1) and after
application of the YELLOW 560 nm filter (Fig. 2). Dis-
section of the facial nerve was feasible for the ENT sur-
geon by using the PENTERO 900 microscope and the
filter. There was excellent visualization of the surgical
field and a remarkable contrast between the facial nerve
and the surrounding tissue. Compared to the standard
technique of tumor resection under white light (Fig. 3),
the enhanced contrast of tumor tissue and possible satel-
lite nodules by using the YELLOW 560 nm filter (Fig. 4)
was estimated as beneficial, meaning that the fluores-
cence staining of the tumor margins was significantly
better than under white light.
We encountered no adverse events or allergic reac-
tions. One patient had a transient weakness of the tem-
poral branch, which was completely reversible in the
follow-up of our out-patient clinic.
Discussion
Goals of parotidectomy surgery include complete and
intact tumor removal with preservation of facial nerve
integrity and function [2]. The literature suggests that
the rate of permanent facial palsy is approximately 2–6%
after parotidectomy [3]. Transient post-operative facial
nerve impairment is observed in 25% to 60% of patients
[4]. A current review by Quer et al. comments on the
history and classification of parotidectomies by the
European Salivary Gland Society [5]. There exist con-
flicting reports, especially concerning the appropriate
technique to remove pleomorphic adenoma, the most
frequent type of parotid tumors. About 20% of all pleo-
morphic adenomas contain abnormalities such as
Table 1 Characteristics of patients including histopathological
reports and observed complications
Patients Age Gender Histopathology Complications
1 45 female Warthin tumor None
2 65 male Warthin tumor None
3 30 female Pleomorphic adenoma Temporary
weakness of the
temporal branch
4 65 female Pleomorphic adenoma None
5 18 male Warthin tumor None
6 78 male Pleomorphic adenoma None
7 74 female Pleomorphic adenoma None
Fig. 1 Surgical view using the PENTERO 900 surgical microscope under white light
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satellite nodules or pseudopodia [6]. Revision surgery in
those cases is associated with higher complication rates
[7]. For this reason many authors prefer lateral (or total)
parotidectomy rather than extracapsular dissection in
these cases [8]. Visualization of the tumor and its mar-
gins is critical to achieving complete tumor removal. In
our case series using intravenously low-dose FL and a
560 nm filter, the tumor visualization was assessed as
better than under white light in 2/7 cases by a single ex-
perienced surgeon. According to the surgeon’s assess-
ment in our present study, the tumor resection might
have been incomplete in 2 cases without the fluorescein
sodium-guided approach. Recurrences of Warthin tu-
mors are rare. But the current literature does not
clearly answer the question what significance residual
tumor tissue in those cases has on the long term.
That is why we believe that complete tumor removal
and preserving the facial nerve is essential in any
kind of parotid gland surgery.
Vaiman et al. recently documented the successful use
of methylene blue in parotid surgery [9]. Similar to the
impressions of our feasibility study on FL, those authors
reported better visualization of the surgical field and de-
scribed more precise localization of the tumor after
methylene blue staining. The rate of recurrences in the
group with staining was significantly lower [9].
The usefulness of fluorescein sodium (FL) under fil-
tered light (e.g. Y560 filter) for resecting malignant brain
tumors has been documented in several case series [1,
10, 11] in our institution. The use of FL in combination
with the 560 nm filter and the PENTERO microscope
for parotidectomy was a logical conclusion. The fluoro-
phore FL has been well known in ophthalmic surgery for
almost five decades and has become established in
neuro-oncologic surgery since the late 1990s [12]. The
fluorescent staining of brain tumors is explained by to
the lack of normal blood–brain barrier function [13]. Ex-
posure to yellow- filtered light with a wavelength of
Fig. 2 Surgical view using the PENTERO 900 microscope with a YELLOW 560 nm filter
Fig. 3 Intraoperative visualization of a parotid gland tumor by the PENTERO 900 surgical microscope without filter. No residual tumor is visible
under white light
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about 560 nm significantly increases the color intensity
of FL [12].
The First National European Pharmacologic Agency
has approved FL for use in neurosurgery (Agenza Itali-
ana del Farmaco ‘AIFA’, determina n.905/2015, 15 luglio
2015) in 2015. George E. Moore was the pioneer of FL-
guided surgery for malignant tumors. He documented
the first results of 46 patients mostly with tumors of the
gastrointestinal tract and the brain [14]. The current
body of literature contains only two reports about ana-
phylactic reactions after FL application [15, 16]. In the
present case series of patients with parotid gland tumors
also no adverse effects were observed. However, the im-
mediate but transient yellow discoloration of the skin
and the urine is consistently described in the literature
[12]. Patients have to be informed and consented. After
the application, FL is completely excreted within 24 h.
We describe for the first time the use of FL in combin-
ation with a 560 nm filter for the resection of benign
parotid tumors. The visualization of the surgical field
was estimated as ‘excellent’ in all cases. In 6/7 cases, the
ENT surgeon used the filter mode predominantly, be-
cause visual contrast appeared enhanced and dissection
and coagulation was easily conducted without affecting
the operative workflow. The operative time was between
2 h and 3 h which is similar to standard conditions. FL
does not require prevention from light and is readily
available in most institutions because of its use in oph-
thalmology procedures. A cost benefit analysis has been
conducted for fluorescein sodium in neurosurgery in
2016. Eljamel et al. compared the effectiveness and cost-
effectiveness of fluorescein sodium, 5-aminolevulinic
acid (´5-ALA´), intraoperative ultrasound and intraoper-
ative magnetic resonance imaging (MRI). The authors
concluded that fluorescein sodium had the most benefi-
cial effect on extent of resection in brain tumors while
the incremental costs were the lowest (by far) [17]. In
Germany, one vial of fluorescein sodium costs approx.
25 €. The present paper presents for the first time data
of Fluorescein Sodium-Guided surgery of parotid gland
tumors. The focus was on the feasibility and safety of
the method. Due to the small sample size, further stud-
ies including more patients with different tumor entities
are necessary.
Conclusion
The use of FL in parotidectomy is promising. In two
cases residual tumor was detected under FL that would
have been left behind under white light. Further research
in parotid gland surgery and other head and neck tumor
procedures is warranted. This report should serve as a
feasibility study, mainly serving as the basis for future
prospective research on the possible benefit of fluores-
cein sodium in parotid surgery.
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